A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2010

Conditions

Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients

Interventions

DRUG

Vehicle

Placebo cream

DRUG

LDE225 0.25%

DRUG

LDE225 0.75%

Trial Locations (3)

Novartis Investigative Site, Graz

Novartis Investigator Site, Vienna

Novartis Investigative Site, Zurich